ROCÍO
GARCÍA CARBONERO
Profesora titular de universidad
![Foto de Enrique](/img/nophoto.png)
Enrique
Grande Pulido
Publikationen, an denen er mitarbeitet Enrique Grande Pulido (24)
2024
2023
-
SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2692-2706
-
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
European Journal of Cancer, Vol. 188, pp. 39-48
2022
-
ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors
Journal of Neuroendocrinology, Vol. 34, Núm. 3
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
-
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
The oncologist, Vol. 27, Núm. 4, pp. e328-e339
-
Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors
Neuroendocrinology, Vol. 112, Núm. 12, pp. 1155-1167
2021
-
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312
-
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial
Oncologist, Vol. 26, Núm. 11, pp. 941-949
2020
-
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)
Oncologist, Vol. 25, Núm. 9, pp. 745-e1265
2019
-
Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review
Therapeutic Advances in Endocrinology and Metabolism, Vol. 10
-
Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544
-
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580
-
Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma
Oncologist, Vol. 24, Núm. 10, pp. 1375-1383
2018
-
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors
Oncologist, Vol. 23, Núm. 7, pp. 766-e90
-
Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours
Cancer Treatment Reviews, Vol. 70, pp. 209-222
2017
-
Optimizing somatostatin analog use in well or moderately differentiated gastroenteropancreatic neuroendocrine tumors
Current Oncology Reports, Vol. 19, Núm. 11
-
Translational research in neuroendocrine tumors: Pitfalls and opportunities
Oncogene, Vol. 36, Núm. 14, pp. 1899-1907
2016
2015
-
Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors
Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 381-400